Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Epilepsy, physical comorbidity and medication review
Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Prolonged or repeated seizure emergency
A convulsive seizure lasting five minutes or more, repeated seizures without usual recovery, serious injury, breathing compromise, a seizure in pregnancy or a pattern outside the person's agreed emergency plan requires an emergency response. A first suspected seizure or recurrence after remission still requires urgent clinical and specialist assessment after recovery.
Action: Protect from injury, time the event, support airway and breathing, check glucose, use the person's prescribed rescue plan if trained and authorised, call emergency services according to duration and plan, and do not restrain movement or place anything in the mouth.
Overview
Recognise and document seizures accurately in people with learning disability, prevent avoidable physical and treatment harm, discuss individual mortality risk accessibly, and coordinate at least annual epilepsy and medication review with specialist input when needed.
Epilepsy is common in people with learning disability, especially where the underlying neurodevelopmental condition also affects cortical organisation. Accurate diagnosis still requires a convincing seizure history and specialist assessment. Ask the person and eyewitnesses what happened immediately before, during and after an event; record awareness, automatisms, symmetry, eye and head position, colour, breathing, continence, duration and recovery. Phone video can be valuable when obtained safely and with appropriate privacy. A label inherited from childhood should be revisited if events or response no longer fit.
Consider mimics and precipitants. Syncope may have brief jerking, psychogenic non-epileptic attacks can coexist with epilepsy, and pain, reflux, dystonia, stereotypy, sleep disorders or behavioural distress may look paroxysmal. Check glucose and acute illness where relevant; review fever, sleep loss, alcohol, substances, missed doses and medicine changes. NICE recommends urgent specialist assessment after a first suspected seizure and after recurrence following remission. Disability should lead to communication and access support, never automatic exclusion from EEG, MRI, genomic assessment or tertiary services.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
PsychiatryOriginal SBA
Annual epilepsy review
An adult with learning disability has apparently stable epilepsy and receives antiseizure medication through a supported-living service. What monitoring frequency does NICE specify?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Each person needs a practical seizure plan in their own accessible format and in records used by family, paid carers, ambulance and day services. Describe usual seizure types, expected recovery, first aid, when to time and call for help, prescribed rescue medication with route and authorised administration, and when an event is outside the plan. Train supporters and check competence. Review bathing, swimming, cooking, heights, fire, travel, driving and night-time arrangements proportionately, preserving autonomy rather than applying blanket restrictions.
NICE calls for at least annual review in adults with epilepsy and learning disability. Review seizure frequency and type, injuries, admissions, rescue use, adherence, adverse effects, mood, cognition, bone and reproductive health, comorbid disease and the person's goals. Reconcile GP, neurology, psychiatry and care-home records because antiseizure medicines may also be prescribed for mood or pain. Look for psychotropic interactions and cumulative sedation, anticholinergic load, falls, dysphagia and reduced participation. A quiet person on more medication is not necessarily better controlled.
Epilepsy carries premature-mortality risk, including sudden unexpected death in epilepsy. NICE identifies potentially modifiable factors including non-adherence, alcohol or drug misuse, uncontrolled focal-to-bilateral or generalised tonic-clonic seizures, living alone and sleeping alone without supervision. Discuss individual risk from diagnosis and revisit it as seizures or circumstances change. Support adherence and seizure control; for higher-risk nocturnal seizures, discuss whether the person wishes to consider night-time supervision or monitoring after individual assessment. This is shared risk reduction, not compulsory surveillance.
Reproductive safety must be explicit and accessible. Current MHRA measures mean valproate must not be newly started in anyone under fifty-five unless two specialists independently consider and document that no other effective or tolerated treatment exists or there are compelling reasons the reproductive risks do not apply. Women and girls able to become pregnant must meet the valproate Pregnancy Prevention Programme when it is the only suitable option: exclude pregnancy, use highly effective contraception, undergo annual specialist review and complete the Annual Risk Acknowledgement Form. At the next annual review, a woman or girl never previously reviewed by two specialists needs a second specialist signature to continue; later annual reviews require one specialist. Male patients under fifty-five complete the Male Risk Acknowledgement Form with the two specialists when starting valproate, while men already taking it do not need a second-specialist review solely because they are male. Counsel male patients about possible reproductive and neurodevelopmental risk, recommend condoms plus contraception used by a female partner during treatment and for three months after stopping, and advise no sperm donation over the same interval. Topiramate is
Key points
Use eyewitness description and video where available to classify suspected seizures; establish onset, awareness, movement, colour, breathing, duration, recovery, injuries and possible triggers.
Learning disability does not make every unusual movement epileptic, and it must not block ordinary EEG, imaging, genetic, tertiary or surgical assessment when clinically indicated.
Create an accessible seizure and emergency plan stating usual events, timing threshold, first aid, rescue medicine, escalation, postictal care and who may administer treatment.
NICE advises at least annual monitoring review for adults with epilepsy and learning disability, with more frequent review for ongoing seizures, high SUDEP risk, serious comorbidity or complex medicines.
Review every antiseizure and psychotropic medicine for indication, seizure effect, interactions, adverse effects, adherence, formulation, swallowing, administration records and person-centred goals.
Discuss epilepsy-related death and SUDEP from diagnosis in an accessible, individualised way, including the importance of seizure control, adherence and relevant night-time risk.
Do not stop antiseizure medicine abruptly; withdrawal after sustained seizure freedom requires individual specialist assessment, a gradual plan and discussion of recurrence and SUDEP risk.
Aetiology
01
Shared neurodevelopmental cause
Genetic, cortical malformation and early brain-injury conditions can produce both learning disability and an enduring susceptibility to epileptic seizures.
02
Acquired cerebral insult
Central nervous system infection, hypoxia, trauma, stroke and tumour may create recurrent seizure risk and additional functional impairment.
03
Provoking factors
Missed medication, acute illness, sleep loss, alcohol, substances and interacting medicines can lower seizure threshold without being the underlying epilepsy cause.
Pathophysiology
1
Network hypersynchrony
Abnormally synchronised neuronal firing produces transient motor, sensory, autonomic, cognitive or awareness change according to the involved network.
2
Propagation
A focal discharge may remain local or spread through bilateral networks, explaining evolution from an aura or impaired awareness to tonic-clonic activity.
3
Postictal suppression
Temporary network exhaustion after a seizure causes confusion, sleep, weakness or altered behaviour and can compromise airway protection.
4
Treatment interaction
Antiseizure and psychotropic medicines alter excitability and metabolism, so enzyme effects, additive sedation and withdrawal can change control and toxicity.
Clinical features and red flags
Focal seizure pattern
Stereotyped sensory, autonomic, cognitive or motor onset may occur with retained or impaired awareness and can progress to bilateral convulsion.
Generalised convulsion
Abrupt loss of awareness with bilateral tonic then clonic movement, breathing and colour change, followed by confusion, sleep or muscle pain supports a tonic-clonic seizure.
Atypical or mixed events
Several seizure types, drop attacks, subtle absences or nocturnal events may coexist, particularly in developmental and genetic epilepsy syndromes.
Medicine burden
Daytime sleep, falls, swallowing difficulty, tremor, behavioural change or lost skills may reflect adverse effects, interactions or excessive polytherapy.
Raised mortality risk
Ongoing tonic-clonic seizures, poor adherence, substance use and unsupervised night-time seizures increase concern for epilepsy-related death and SUDEP.
Red flags requiring action
A first suspected seizure or recurrence after remission requires urgent specialist assessment; collapse may instead be syncope, arrhythmia, hypoglycaemia, dissociation or another cause.
Prolonged convulsion, incomplete recovery, cyanosis, major injury, focal deficit, fever, pregnancy or a substantially changed seizure pattern needs emergency evaluation.
Investigations
01Eyewitness history and safe videoFirst step
Why
Characterise onset, semiology, duration and recovery and distinguish likely seizure from a mimic.
Interpretation and limitations
Stereotyped recurrence and a coherent sequence support classification; video supplements but never replaces history, examination and specialist judgement.
02Twelve-lead ECG after first event
Why
Identify cardiac conditions that can present as transient loss of consciousness.
Interpretation and limitations
An abnormality prompts appropriate cardiac assessment; a normal ECG neither proves epilepsy nor excludes intermittent arrhythmia.
03EEG selected by specialist question
Why
Support seizure type or syndrome classification when the clinical history suggests epilepsy.
Interpretation and limitations
Epileptiform activity supports risk and classification, but a normal interictal EEG does not exclude epilepsy and EEG must not be used to exclude a likely mimic indiscriminately.
04Brain imaging and genomic assessment
Why
Identify structural or genetic aetiology when NICE clinical criteria are met.
Interpretation and limitations
Learning disability can strengthen an indication for genomic assessment and must not prevent MRI or tertiary evaluation where findings could alter treatment.
05
Differential diagnosis
01
Syncope
Circulatory collapse often has prodromal light-headedness, pallor and rapid recovery, although brief stiffening or jerks may occur during cerebral hypoperfusion.
02
Psychogenic non-epileptic event
Functional attacks require positive specialist assessment and may coexist with epilepsy; neither disability nor psychological stress alone establishes the diagnosis.
03
Movement or behavioural event
Stereotypy, dystonia, tremor, reflux, pain response and sleep phenomena can be recurrent and visually mistaken for seizures.
04
Acute metabolic event
Hypoglycaemia, electrolyte disturbance, infection, intoxication and medicine toxicity can provoke seizure or altered consciousness needing urgent cause-specific treatment.
Management
01Suspected eventDescribe before classifyingFirst stepA first, recurrent or changed paroxysmal event may represent an epileptic seizure.+
1Obtain the person's and eyewitness accounts, safe video if available, event timing, recovery, injuries, medicines, acute illness, substances and prior baseline.
2Assess physical and neurological findings, glucose and ECG or other urgent causes according to the presentation, treating status or injury immediately.
3Refer urgently for specialist assessment after a first suspected seizure or recurrence after remission and make interim first-aid and safety advice accessible.
02Established epilepsyIntegrate seizure and medicine reviewA person with learning disability has active epilepsy or continuing antiseizure treatment.+
1Reconcile seizure types, frequency, recovery, rescue use, injuries, admissions and the indication and administration of every antiseizure and psychotropic medicine.
Complications
01
Status and injury
Prolonged or repeated seizures can cause hypoxia, aspiration, trauma and neurological harm and require prompt emergency treatment.
02
Premature mortality
SUDEP, drowning, accident, aspiration and underlying neurological disease contribute to increased epilepsy-related death, particularly with uncontrolled tonic-clonic seizures.
03
Medicine toxicity
Polytherapy can cause sedation, ataxia, cognitive slowing, mood change, bone effects, reproductive harm and clinically important interactions.
04
Restrictive living
Overbroad safety rules may unnecessarily remove privacy, employment, activity and choice when individual risk assessment and adaptations could preserve participation.
Monitoring and follow-up
Arrange regular review at least annually for every adult with epilepsy and learning disability, and more often when seizures, high SUDEP risk, serious comorbidity or complex treatment require it.
Maintain a seizure record distinguishing type, duration, recovery, injury, rescue medicine and possible precipitants, using a format the person and supporters can sustain.
At every medicine review, check indication, formulation, adherence, administration records, interactions, adverse effects, weight, mood, cognition, falls, swallowing and relevant blood monitoring.
Revisit accessible reproductive-risk counselling and current regulatory safeguards for valproate and topiramate, documenting specialist decisions without abrupt discontinuation.
Review SUDEP and epilepsy-related death risk when control or circumstances change, including nocturnal events, living arrangements, alcohol, substances and missed treatment.
Check the emergency plan, rescue-medicine supply, expiry, storage and supporter competence after every use, admission, transition or change in seizure pattern.
Special situations
Jerking can occur in syncope
Brief myoclonic movement after circulatory collapse does not prove epilepsy; prodrome, colour, duration, ECG context and rapid recovery help distinguish events.
Learning disability is no exclusion
NICE explicitly says indicated resective-surgery assessment should not be withheld because a person has learning disability or a genetic abnormality.
SUDEP discussion is preventive
Accessible, individual explanation supports seizure control and adherence; avoiding the topic deprives the person of risk-reduction choices.
Care records may disagree
Neurology, GP, psychiatry and provider lists can attach different indications to the same drug, so reconciliation must establish why each medicine continues.
Common pitfalls
01
Calling every collapse, stare, tremor or repetitive movement epilepsy without a detailed event sequence and differential diagnosis.
02
Excluding a person from MRI, genomic testing, tertiary referral or surgical assessment because communication or learning needs require adjustment.
03
Continuing antiseizure polytherapy because historical prescriptions persist while sedation, falls, swallowing and lost participation are not measured.
04
Avoiding SUDEP discussion because it feels distressing instead of explaining individual risk and modifiable factors accessibly and sensitively.
05
Stopping valproate, benzodiazepine or another antiseizure medicine abruptly after a regulatory or adverse-effect concern without a specialist seizure-safety plan.
06
Writing ‘call an ambulance if needed’ rather than a timed, accessible emergency plan with rescue route, escalation and responsible trained people.
in pregnancy for migraine prevention and, for epilepsy, unless there is no suitable alternative. Women and girls able to become pregnant must meet its Pregnancy Prevention Programme: exclude pregnancy before starting, use highly effective contraception during treatment and for at least four weeks after the last dose, and complete a Risk Awareness Form at initiation and at least annually. Check contraceptive interactions. If pregnancy is planned or suspected during epilepsy treatment, obtain urgent specialist advice and
do not
stop valproate or topiramate abruptly.
Uncontrolled bilateral tonic-clonic seizures, missed antiseizure medicine, alcohol or drug misuse and sleeping or living alone increase epilepsy-related death risk and require an individual prevention discussion.
New sedation, ataxia, tremor, falls, dysphagia, weight change, mood disturbance, rash, bruising or cognitive decline may indicate antiseizure medicine harm or interaction.
Valproate or topiramate exposure without current reproductive-risk review, accessible counselling and required safeguards is a prescribing-safety concern, not a routine repeat issue.
Medication and physical-health review
Why
Detect adherence problems, interactions, adverse effects and comorbidity that change seizure safety.
Interpretation and limitations
Use targeted blood tests when clinically indicated by the medicine or symptoms; routine drug levels are not a substitute for clinical review and correct administration.
2Assess adverse effects, adherence, swallowing, interactions, mental health, bone and reproductive health, activities and supporter training, using reasonable adjustments.
3Arrange at least annual review and earlier specialist or tertiary input for uncontrolled events, diagnostic uncertainty, intolerable effects or potential surgery and advanced treatment.
03Mortality preventionDiscuss SUDEP and reduce modifiable riskEpilepsy is diagnosed or seizure control, adherence or living circumstances alter risk.+
1Explain individual epilepsy-related death and SUDEP risk in an accessible format, involving family or carers when appropriate to the person's wishes and capacity.
2Optimise tonic-clonic seizure control and adherence, address alcohol or drug misuse and correct practical barriers to reliable medicine administration.
3For higher-risk sleep seizures, explore night supervision or monitoring as a shared individual choice and record an emergency and post-seizure response plan.